When: Post-Q3 2026 print with sequential EBITDA growth AND deleveraging progress AND no further impairments

Then: Upgrade path to Hold/Overweight

50% trim floor, full exit upper bound; remove re-entry obligation; stop at 10 EMA $147.60

• IPR&D: $11.2B acquisition with $12.9B write-down (115% haircut) is a structural capital allocation credibility event, not a tactical technical setup
• Forward earnings at risk with 2027 patent cliff on Biktarvy (concentrated HIV franchise)
• Net debt rose 58% in a single quarter; 2.19% dividend yield no longer serves as safe harbor with impaired management credibility
• Volume profile: recovery from $121 to $151 on compressed volume (low participation) vs 22% drawdown on heavy volume during spring correction signals distribution, not accumulation
• IRA Medicare negotiation expands annually; large cap pharma with concentrated franchises is a structural policy target
• Biktarvy dominant share of HIV revenue; GSK long-acting injectable and lenacapavir disruption in PrEP space is a base case over 24 months, not a tail risk
• Aggressive analyst's 55% combined probability of two distinct negative outcomes requires larger trim than 25-33%—partial trim exposes 65-75% of downside
• Conservative trim floor: 50%; upper bound: full exit with 6-12 month observation period
• Conservative stop: 10 EMA at $147.60 (losing rising short-term trend on closing basis triggers full exit)
• Remove re-entry obligation for at least 2 earnings cycles until LOE timeline clearer and capital allocation credibility restored

→ vs aggressive: 25-33% trim exposes 65-75% of downside described—papered over thesis downgrade with technical re-entry, not genuine risk reduction

→ vs aggressive: Re-entry at $147-148 buys same compromised exposure at better price but worse structural setup; re-entry above $155 is chasing strength after framing current action as exhaustion—two trades wearing same label

→ vs aggressive: IRA Medicare policy regime risk and franchise concentration not priced into technical framework

→ vs aggressive: Pullback to 10 EMA ($147) does not resolve capital allocation problems, franchise patent cliff, or balance sheet leverage

Trim 40% of existing exposure; maintain core long-term position; stop at $143.50; re-enter only on confirmed resolution of structural concerns (clean integration update or successful retest above $155 on volume)

• 40% trim recommended as optimal middle ground between aggressive (25-33%) and conservative (50%/full exit) positions
• Stop at $143.50 (Bollinger middle band, ~1.5-2 ATR below current price) rather than aggressive analyst's $158 (too generous) or conservative's $147.60 (too tight, would tag on normal pullbacks)
• Re-entry gated on confirmed resolution of structural concerns: either clean integration update addressing IPR&D write-down or successful retest of $155 breakout on volume
• Gilead still generates $9.8 billion in FCF with dividend 2.4x covered; HIV franchise continues through patent cliff
• Macro environment (89% probability of zero Fed cuts in 2026, 7% recession odds falling) actively supports holding defensive cash-generative compounders
• Aggressive analyst's $147-148 re-entry zone gives worse risk reward than trim executed and conflates price level with thesis resolution
• Conservative analyst's 6-12 month exit framework is 'selling low because you're scared' and abandons compounding at reasonable multiple

→ vs aggressive: Right about risk setup but hasn't proven specific trim size (25-33%), stop ($158), and re-entry framework ($147) are correct; keeping 65-75% exposure into 55% probability of non-continuation still underperforms disciplined trim if bear case materializes

→ vs conservative: Identifies real structural risks (IRA drug pricing, patent cliff in ~15 months) but wants framework that removes optionality at exactly point of maximum value; cannot call yourself long-term investor and exit every window of uncertainty—this is 'active management equivalent of selling low'

→ vs aggressive: Cannot argue structural risks are real and then claim $147 pullback is a buying opportunity; structural risks don't disappear at lower price levels and $147 pullback maximizes exposure to follow-through selling toward $136 50 SMA

→ vs conservative: Treating current environment as 2022 rate shock when Polymarket shows 89% zero Fed cuts in 2026 and 7% recession odds falling; macro is actively dampening the tail risks he's protecting against